{"id":1067938,"date":"2021-12-21T01:45:50","date_gmt":"2021-12-21T06:45:50","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/opiant-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/"},"modified":"2024-08-18T11:41:08","modified_gmt":"2024-08-18T15:41:08","slug":"opiant-reports-inducement-grants-under-nasdaq-listing-rule-5635c4","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/opiant-reports-inducement-grants-under-nasdaq-listing-rule-5635c4.php","title":{"rendered":"Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<p><![CDATA[SANTA MONICA, Calif., Dec.  20, 2021  (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc.\u00a0(\u201cOpiant\u201d or \u201cCompany\u201d) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the Compensation Committee of the Company\u2019s Board of Directors has approved the grant of restricted stock units (\u201cRSU\u201d) covering an aggregate of 31,500 shares of common stock to six hired employees, pursuant to the Company\u2019s 2021 Inducement Equity Incentive Plan (\u201cInducement Plan\u201d). The RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).]]><\/p>\n<p>See the original post here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2021\/12\/20\/2355647\/0\/en\/Opiant-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\">Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>See the original post here: Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/opiant-reports-inducement-grants-under-nasdaq-listing-rule-5635c4.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1067938","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1067938"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1067938"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1067938\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1067938"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1067938"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1067938"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}